Kinetics of Adaptive Immune Responses After Administering MRNA-Based COVID-19 Vaccination in Individuals with and Without Prior SARS-CoV-2 Infections

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Oct 27

PMID 37891503

Authors

Sun-Woo Yoon

Kristin Widyasari

Jieun Jang

Seungjun Lee

Taejoon Kang

Sunjoo Kim

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to compare the adaptive immune response in individuals with or without prior SARS-CoV-2 infections following the administration of mRNA-based COVID-19 vaccines.

Methods: A total of 54 participants with ages ranging from 37 to 56 years old, consisting of 23 individuals without a history of SARS-CoV-2 infection (uninfected group) and 31 individuals with prior infection of SARS-CoV-2 (infected group) who have received two doses of mRNA SARS-CoV-2 vaccines were enrolled in this study. We measured the IFN-γ level upon administration of BNT162b2 (PF) or mRNA-1273 (MO) by QuantiFERON SARS-CoV-2. The production of neutralizing antibodies was evaluated by a surrogate virus neutralization assay, and the neutralizing capacity was assessed by a plaque reduction neutralization test (PRNT). The immune response was compared between the two groups.

Results: A significantly higher level of IFN-γ (p < 0.001) and neutralization antibodies (p < 0.001) were observed in the infected group than those in the uninfected group following the first administration of vaccines. The infected group demonstrated a significantly higher PRNT titer than the uninfected group against the Wuhan strain (p < 0.0001). Still, the two groups were not significantly different against Delta (p = 0.07) and Omicron (p = 0.14) variants. Following the second vaccine dose, T- and B-cell levels were not significantly increased in the infected group.

Conclusion: A single dose of mRNA-based COVID-19 vaccines would boost immune responses in individuals who had previously contracted SARS-CoV-2.

Citing Articles

Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.

Mukenge E, Sumbu B, Nkodila A, Muwonga J, Makulo J, Ngole M BMC Infect Dis. 2025; 25(1):342.

PMID: 40069636 PMC: 11899428. DOI: 10.1186/s12879-025-10754-4.

Validation of the Enzyme-Linked ImmunoSpot Analytic Method for the Detection of Human IFN-γ from Peripheral Blood Mononuclear Cells in Response to the SARS-CoV-2 Spike Protein.

Carreto-Binaghi L, Nieto-Ponce M, Palencia-Reyes A, Chavez-Dominguez R, Blancas-Zaragoza J, Franco-Mendoza P Biomolecules. 2024; 14(10).

PMID: 39456219 PMC: 11506497. DOI: 10.3390/biom14101286.

References

Gee J, Marquez P, Su J, Calvert G, Liu R, Myers T . First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283-288. PMC: 8344985. DOI: 10.15585/mmwr.mm7008e3. View

Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M . The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(50):1922-1924. PMC: 7745957. DOI: 10.15585/mmwr.mm6950e2. View

Reynolds C, Pade C, Gibbons J, Butler D, Otter A, Menacho K . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021; . PMC: 8168614. DOI: 10.1126/science.abh1282. View

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

Jacobsen H, Cobos Jimenez V, Sitaras I, Bar-Zeev N, Cicin-Sain L, Higdon M . Post-vaccination T cell immunity to omicron. Front Immunol. 2022; 13:944713. PMC: 9386871. DOI: 10.3389/fimmu.2022.944713. View

Wherry E, Kurachi M . Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8):486-99. PMC: 4889009. DOI: 10.1038/nri3862. View

Lau E, Tsang O, Hui D, Kwan M, Chan W, Chiu S . Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021; 12(1):63. PMC: 7782739. DOI: 10.1038/s41467-020-20247-4. View

Nandakumar V, Profaizer T, Lozier B, Elgort M, Larragoite E, Williams E . Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Arch Pathol Lab Med. 2021; 145(10):1212-1220. DOI: 10.5858/arpa.2021-0213-SA. View

Goel R, Apostolidis S, Painter M, Mathew D, Pattekar A, Kuthuru O . Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021; 6(58). PMC: 8158969. DOI: 10.1126/sciimmunol.abi6950. View

10.

Hurme A, Jalkanen P, Heroum J, Liedes O, Vara S, Melin M . Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. Front Immunol. 2022; 13:869990. PMC: 9073085. DOI: 10.3389/fimmu.2022.869990. View

11.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

12.

Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene W . mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife. 2021; 10. PMC: 8545397. DOI: 10.7554/eLife.72619. View

13.

Park J, Lagniton P, Liu Y, Xu R . mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021; 17(6):1446-1460. PMC: 8071766. DOI: 10.7150/ijbs.59233. View

14.

Widyasari K, Jang J, Lee S, Kang T, Kim S . Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. J Microbiol Immunol Infect. 2022; 55(6 Pt 1):1013-1024. PMC: 9516877. DOI: 10.1016/j.jmii.2022.09.004. View

15.

Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G . Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021; 26(26). PMC: 8326656. DOI: 10.2807/1560-7917.ES.2021.26.26.2100557. View

16.

Chagla Z . In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose. Ann Intern Med. 2021; 174(3):JC28. DOI: 10.7326/ACPJ202103160-028. View

17.

Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M . The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(5152):1653-1656. PMC: 9191904. DOI: 10.15585/mmwr.mm695152e1. View

18.

Collier A, Yu J, McMahan K, Liu J, Chandrashekar A, Maron J . Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. N Engl J Med. 2021; 385(21):2010-2012. PMC: 8531985. DOI: 10.1056/NEJMc2115596. View

19.

Barton M, MacGowan S, Kutuzov M, Dushek O, Barton G, Anton van der Merwe P . Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021; 10. PMC: 8480977. DOI: 10.7554/eLife.70658. View

20.

Goldblatt D, Alter G, Crotty S, Plotkin S . Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022; 310(1):6-26. PMC: 9348242. DOI: 10.1111/imr.13091. View